Summary
IDP Chart
New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA
CAMBRIDGE, Mass., June 27, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced new data that reinforce the clinical impact of nusinersen across a broad spectrum of individuals affected by spinal muscular atrophy (SMA). These latest findings from Part C of the DEVOTE trial evaluating a higher dose regimen of nusinersen and the NURTURE trial which evaluated the approved 12 mg regimen (SPINRAZA®) in clinically presymptomatic SMA were presented at the SMA Research & Clinical Care Meeting hosted by Cure SMA in Anaheim, Calif. Biogen's applications for the higher dose regimen of nusinersen are currently under review in the U.S., Europe, Japan and other global markets. The higher dose regimen of nusinersen comprises a more rapid loading regimen – two 50 mg doses 14 days apart – and a higher maintenance regimen – 28 mg every four months.
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced topline results from the Phase 1 study of salanersen (BIIB115/ION306), an antisense oligonucleotide (ASO) being developed for the treatment of spinal muscular atrophy (SMA). Leveraging the same mechanism of action as SPINRAZA (nusinersen) but designed to achieve greater potency, salanersen has the potential to achieve high efficacy and enable once yearly dosing. An interim analysis of the Phase 1 study in participants with SMA who were previously treated with gene therapy was conducted to inform the decision on whether to move salanersen forward into registrational studies. Both dose levels tested, 40 mg and 80 mg, given once a year, were generally well-tolerated and led to substantial slowing of neurodegeneration, as shown by reductions in neurofilament. Exploratory clinical outcome data shows clinically meaningful improvements in function and attainment of new World Health Organization (WHO) milestones over 1 year. These data will be presented today at the SMA Research & Clinical Care Meeting hosted by Cure SMA in Anaheim, Calif.
Biogen: Investors Are Missing The Bigger Picture
Biogen is an intriguing stock that occupies one of the leading positions in the central nervous system therapeutic market. On May 1, it released fairly strong financial results for the first quarter of 2025. So, the strong demand for Skyclarys and Leqembi helps strengthen Biogen's balance sheet and also allows it to actively rejuvenate its portfolio of product candidates aimed at treating autoimmune diseases.
Biogen Inc. Dividends
 BIIB 2 Feb 2017 Paid | Other | $22.23 Per Share |
Biogen Inc. Earnings
| 30 Jul 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
| 22 Apr 2025 Date | | - Cons. EPS | - EPS |
| 11 Feb 2025 Date | | 3.36 Cons. EPS | 3.44 EPS |
| 6 Nov 2024 Date | | 3.79 Cons. EPS | - EPS |
| 30 Oct 2024 Date | | 3.79 Cons. EPS | 4.08 EPS |
| BIIB 2 Feb 2017 Paid | Other | $22.23 Per Share |
| 30 Jul 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
| 22 Apr 2025 Date | | - Cons. EPS | - EPS |
| 11 Feb 2025 Date | | 3.36 Cons. EPS | 3.44 EPS |
| 6 Nov 2024 Date | | 3.79 Cons. EPS | - EPS |
| 30 Oct 2024 Date | | 3.79 Cons. EPS | 4.08 EPS |
Biogen Inc. (IDP) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Biogen Inc. ever had a stock split?
Biogen Inc. Profile
| Drug Manufacturers - General Industry | Healthcare Sector | Christopher A. Viehbacher CEO | XHAN Exchange | US09062X1037 ISIN |
| US Country | 7,605 Employees | - Last Dividend | 18 Jan 2001 Last Split | 16 Sep 1991 IPO Date |
Overview
Biogen Inc. is a pioneering biopharmaceutical company focused on discovering, developing, manufacturing, and delivering innovative therapies for neurological and neurodegenerative diseases. With a broad international presence, Biogen extends its reach across the United States, Europe, Germany, Asia, and other global regions. Since its founding in 1978, Biogen has been at the forefront of addressing some of the most challenging medical conditions, including multiple sclerosis (MS), spinal muscular atrophy, Alzheimer's disease, and psoriasis, among others. The company operates in collaboration with several notable industry partners, such as Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; and others, to advance its mission of transforming scientific discoveries into medical breakthroughs. Headquartered in Cambridge, Massachusetts, Biogen's commitment to improving patient care continues to drive its innovative research and drug development strategies.
Products and Services
Biogen's diverse portfolio showcases its dedication to treating complex neurological and neurodegenerative conditions:
- TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA: These products are part of Biogen's multiple sclerosis (MS) treatment range, addressing various aspects of MS management to improve patient quality of life.
- SPINRAZA: A groundbreaking therapy for spinal muscular atrophy, offering hope to individuals affected by this genetic disorder.
- ADUHELM: Part of Biogen's Alzheimer's disease portfolio, this drug represents a significant advancement in treating a condition that affects millions of individuals worldwide.
- FUMADERM: Developed for the treatment of plaque psoriasis, demonstrating Biogen's commitment to addressing autoimmune skin conditions.
- Biosimilars (BENEPALI, IMRALDI, FLIXABI, BYOOVIZ): These etanercept, adalimumab, infliximab, and ranibizumab biosimilars offer cost-effective alternatives to some of the most widely used biologic therapies for autoimmune diseases and macular degeneration.
- RITUXAN (and RITUXAN HYCELA), GAZYVA, OCREVUS: Biogen's offerings in the oncology and MS spaces, including treatments for non-Hodgkin's lymphoma, CLL, rheumatoid arthritis, and primary progressive MS, highlight the company's strong presence in developing therapies for both cancer and autoimmune diseases.
- LUNSUMIO, glofitamab, and other anti-CD20 therapies: These therapies are designed for patients with relapsed or refractory follicular lymphoma and non-Hodgkin's lymphoma, showcasing Biogen’s ongoing dedication to innovative cancer treatment.
In addition, Biogen's pipeline includes a broad array of projects targeting MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease, neuropsychiatry, genetic neurodevelopmental disorders, and the development of biosimilars. These initiatives, under various stages of development, signify Biogen's enduring commitment to expanding its impact on unmet medical needs and improving the lives of patients around the globe.
Contact Information
